Improving Medication Compliance in Patients With Heart Failure

American Journal of Cardiology

Volumn 101, Issue 2, 2008, Pages 274-277

  Brown, Suzanne B ^a   Shannon, Richard P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL MALEATE; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; HYDRALAZINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; ISOSORBIDE DINITRATE; METFORMIN; ROSIGLITAZONE; SPIRONOLACTONE;

ACCURACY; AGING; CLINICAL ASSESSMENT; COMORBIDITY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DOSE TIME EFFECT RELATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; EDITORIAL; FUNCTIONAL STATUS; HEART FAILURE; HEART INFARCTION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; MONOTHERAPY; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SOCIOECONOMICS; TREATMENT OUTCOME; UNITED STATES;

DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; PATIENT COMPLIANCE; UNITED STATES;

EID: 37549030124     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.07.073     Document Type: Editorial

References (41)

1. American Heart Association. Heart disease and stroke statistics-2006 update (2006), American Heart Association, Dallas, Texas 1-43
2. Kannel W.B., Castelli W.P., McNamara P.M., McKee P.A., and Feinleib M. Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med 287 (1972) 781-787
3. American Heart Association. Heart disease and stroke statistics-2007 update (2007), American Heart Association, Dallas, Texas 1-43
4. McMurray J., Cohen-Solal A., Dietz R., Eichhorn E., Erhardt L., Hobbs F.D., Krum H., Maggioni A., McKelvie R.S., Pina I.L., et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail 7 (2005) 710-721
5. Masoudi F.A., Baillie C.A., Wang Y., Bradford W.D., Steiner J.F., Havranek E.P., Foody J.M., and Krumholz H.M. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. Arch Intern Med 165 (2005) 2069-2076
6. Fletcher S.W., Pappius E.M., and Harper S.J. Measurement of medication compliance in a clinical setting. Comparison of three methods in patients prescribed digoxin. Arch Intern Med 139 (1979) 635-638
7. van der Wal M.H., Jaarsma T., and van Veldhuisen D.J. Non-compliance in patients with heart failure; how can we manage it?. Eur J Heart Fail 7 (2005) 5-17
8. Monane M., Bohn R.L., Gurwitz J.H., Glynn R.J., and Avorn J. Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med 154 (1994) 433-437
9. Cline C.M., Bjorck-Linne A.K., Israelsson B.Y., Willenheimer R.B., and Erhardt L.R. Non-compliance and knowledge of prescribed medication in elderly patients with heart failure. Eur J Heart Fail 1 (1999) 145-149
10. Roe C.M., Motheral B.R., Teitelbaum F., and Rich M.W. Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure. Am Heart J 138 (1999) 818-825
11. Ekman I., Andersson G., Boman K., Charlesworth A., Cleland J.G., Poole-Wilson P., and Swedberg K. Adherence and perception of medication in patients with chronic heart failure during a five-year randomised trial. Patient Educ Couns 61 (2006) 348-353
12. Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., Michelson E.L., Olofsson B., Ostergren J., Yusuf S., and Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
13. Evangelista L., Doering L.V., Dracup K., Westlake C., Hamilton M., and Fonarow G.C. Compliance behaviors of elderly patients with advanced heart failure. J Cardiovasc Nurs 18 (2003) 197-206
14. Straka R.J., Fish J.T., Benson S.R., and Suh J.T. Magnitude and nature of noncompliance with treatment using isosorbide dinitrate in patients with ischemic heart disease. J Clin Pharmacol 36 (1996) 587-594
15. Stewart S., and Horowitz J.D. Detecting early clinical deterioration in chronic heart failure patients post-acute hospitalisation-a critical component of multidisciplinary, home-based intervention?. Eur J Heart Fail 4 (2002) 345-351
16. Cole J.A., Norman H., Weatherby L.B., and Walker A.M. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes. Pharmacotherapy 26 (2006) 1157-1164
17. Hope C.J., Wu J., Tu W., Young J., and Murray M.D. Association of medication adherence, knowledge, and skills with emergency department visits by adults 50 years or older with congestive heart failure. Am J Health Syst Pharm 61 (2004) 2043-2049
18. Joshi P.P., Mohanan C.J., Sengupta S.P., and Salkar R.G. Factors precipitating congestive heart failure-role of patient non-compliance. J Assoc Physicians India 47 (1999) 294-295
19. Michalsen A., Konig G., and Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 80 (1998) 437-441
20. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 (1997) 525-533
21. Miura T., Kojima R., Mizutani M., Shiga Y., Takatsu F., and Suzuki Y. Effect of digoxin noncompliance on hospitalization and mortality in patients with heart failure in long-term therapy: a prospective cohort study. Eur J Clin Pharmacol 57 (2001) 77-83
22. Artinian N.T., Magnan M., Sloan M., and Lange M.P. Self-care behaviors among patients with heart failure. Heart Lung 31 (2002) 161-172
23. Schwarz E.R., Rastogi S., Kapur V., Sulemanjee N., and Rodriguez J.J. Erectile dysfunction in heart failure patients. J Am Coll Cardiol 48 (2006) 1111-1119
24. Jackson J.E., Doescher M.P., Saver B.G., and Fishman P. Prescription drug coverage, health, and medication acquisition among seniors with one or more chronic conditions. Med Care 42 (2004) 1056-1065
25. Ohene B.K., Matowe L., and Plange-Rhule J. Unaffordable drug prices: the major cause of non-compliance with hypertension medication in Ghana. J Pharm Pharm Sci 7 (2004) 350-352
26. Kulkarni S.P., Alexander K.P., Lytle B., Heiss G., and Peterson E.D. Long-term adherence with cardiovascular drug regimens. Am Heart J 151 (2006) 185-191
27. Chapman R.H., Benner J.S., Petrilla A.A., Tierce J.C., Collins S.R., Battleman D.S., and Schwartz J.S. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 165 (2005) 1147-1152
28. Avorn J., Monette J., Lacour A., Bohn R.L., Monane M., Mogun H., and LeLorier J. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 279 (1998) 1458-1462
29. Monane M., Bohn R.L., Gurwitz J.H., Glynn R.J., Levin R., and Avorn J. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens 10 (1997) 697-704
30. Eisen S.A., Miller D.K., Woodward R.S., Spitznagel E., and Przybeck T.R. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 150 (1990) 1881-1884
31. Greenberg R.N. Overview of patient compliance with medication dosing: a literature review. Clin Ther 6 (1984) 592-599
32. Iskedjian M., Einarson T.R., MacKeigan L.D., Shear N., Addis A., Mittmann N., and Ilersich A.L. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 24 (2002) 302-316
33. Dezii C.M. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care 9 (2000) 2-6
34. Vanderpoel D.R., Hussein M.A., Watson-Heidari T., and Perry A. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther 26 (2004) 2066-2075
35. Melikian C., White T.J., Vanderplas A., Dezii C.M., and Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 24 (2002) 460-467
36. Taylor A.L., Ziesche S., Yancy C., Carson P., D'Agostino Jr. R., Ferdinand K., Taylor M., Adams K., Sabolinski M., Worcel M., and Cohn J.N. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 (2004) 2049-2057
37. Sleight P., Pouleur H., and Zannad F. Benefits, challenges, and registerability of the polypill. Eur Heart J 27 (2006) 1651-1656
38. Law M.R., Wald N.J., Morris J.K., and Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326 (2003) 1427
39. Bristow M.R., Gilbert E.M., Abraham W.T., Adams K.F., Fowler M.B., Hershberger R.E., Kubo S.H., Narahara K.A., Ingersoll H., Krueger S., et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 94 (1996) 2807-2816
40. van Veldhuisen D.J., Genth-Zotz S., Brouwer J., Boomsma F., Netzer T., Man In't Veld A.J., Pinto Y.M., Lie K.I., and Crijns H.J. High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 32 (1998) 1811-1818
41. Angus D.C., Linde-Zwirble W.T., Tam S.W., Ghali J.K., Sabolinski M.L., Villagra V.G., Winkelmayer W.C., Worcel M., and African-American Heart Failure Trial (A-HeFT) Investigators. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation 112 (2005) 3745-3753